On Tuesday, April 11, the next meeting of the Transparency Council.
The agenda includes:
Preparation of positions on drug evaluation:
- Lumykras (sotorasibum) under drug program B.6 "Treatment of patients with lung cancer (ICD-10: C34) and pleural mesoth...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
